Can thyroid histomorphology identify patients with PTEN hamartoma tumour syndrome?
PHTS
PTEN
adenomatous nodule
genetic counselling
thyroid
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
01 Jul 2024
01 Jul 2024
Historique:
revised:
07
06
2024
received:
08
05
2024
accepted:
20
06
2024
medline:
2
7
2024
pubmed:
2
7
2024
entrez:
2
7
2024
Statut:
aheadofprint
Résumé
The phosphatase and tensin homologue (PTEN) hamartoma tumour syndrome (PHTS) is a genetic disorder with variable clinical presentation and increased lifetime risk of multiorgan malignancies. The thyroid gland is commonly affected with follicular nodular disease (FND) and follicular cell-derived carcinomas. Histopathological and immunohistochemical assessment of thyroid disease in PHTS is essential to identify patients at-risk. In all, 30 PHTS patients with available thyroidectomy specimen material (2000-2023) and 31 control patients with FND and "adenomatous nodules" were retrieved. Histologic criteria, including the frequency of adenomatous-type nodules versus hyperplastic-type nodules, background and nodular lipomatous metaplasia, chronic lymphocytic thyroiditis, cytoplasmic clearing of follicular cells in nodules, nodule-in-nodule appearance, and spectrum of nuclear atypia between nodules were evaluated in both cohorts and a Thyroid Histomorphologic PHTS Score (THiPS) system was established with a cutoff of 4 points or higher being considered concerning for PHTS. In all, 27 PHTS (90%) and five control (16.1%) cases had THiPS ≥4. A PTEN immunohistochemical stain was evaluated in 25 cases of each cohort and showed nuclear and cytoplasmic loss of expression in all or most of the nodules of 24/25 PHTS cases. In 3/25 control cases, two with THiPS ≥4, had loss of expression in one to multiple nodules. Conventional papillary thyroid carcinomas in PHTS patients retained PTEN cytoplasmic expression. Our study supports that, although not specific, the finding of multiple histologic features is found more frequently in patients with PHTS compared to the non-PHTS control group. The THiPS system has high sensitivity for thyroid specimens from patients with PHTS.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Histopathology published by John Wiley & Sons Ltd.
Références
Nelen MR, Padberg GW, Peeters EAJ et al. Localization of the gene for Cowden disease to chromosome 10q22–23. Nat. Genet. 1996; 13; 114–116.
Brosens LAA, Jansen M, Foulkes WD, Eberhart CG, Eng CE, Ngeow J. PTEN hamartoma tumor syndrome. In Lester DR, Thompson AJL eds. WHO classifications of tumors editorial board. Genetic Tumor Syndromes. ([Internet, beta version ahead of print]. 5th ed). [cited 2024 February 25]. Available at: https://tumourclassification.iarc.who.int/chaptercontent/67/111. Lyon (France): WHO classification of tumors series, 2023.
Yehia L, Eng C. PTEN hamartoma tumor syndrome. In Adam MP, Feldman J, Mirzaa GM et al. eds. GeneReviews®. Seattle: University of Washington, 1993–2024.
Zhou X‐P, Waite KA, Pilarski R et al. Germline PTEN promoter mutations and deletions in Cowden/Bannayan‐Riley‐Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol‐3‐kinase/Akt pathway. Am. J. Hum. Genet. 2003; 73; 404–411.
Marsh DJ, Coulon V, Lunetta KL et al. Mutation spectrum and genotype‐phenotype analyses in Cowden disease and Bannayan‐Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum. Mol. Genet. 1998; 7; 507–515.
Tan M‐H, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin. Cancer Res. 2012; 18; 400–407.
Yehia L, Plitt G, Tushar AM et al. Longitudinal analysis of cancer risk in children and adults with germline PTEN variants. JAMA Netw. Open 2023; 6; e239705.
Hendricks LAJ, Hoogerbrugge N, Venselaar H et al. Genotype‐phenotype associations in a large PTEN hamartoma tumor syndrome (PHTS) patient cohort. Eur. J. Med. Genet. 2022; 65; 104632.
Milani D, Dolci A, Muller I et al. Thyroid findings in pediatric and adult patients with PTEN hamartoma tumor syndrome: a retrospective analysis, and literature review. Endocrine 2023; 81; 98–106.
Laury AR, Bongiovanni M, Tille J‐C, Kozakewich H, Nosé V. Thyroid pathology in PTEN‐hamartoma tumor syndrome: characteristic findings of a distinct entity. Thyroid 2011; 21; 135–144.
Harach HR, Soubeyran I, Brown A, Bonneau D, Longy M. Thyroid pathologic findings in patients with Cowden disease. Ann. Diagn. Pathol. 1999; 3; 331–340.
Lee Y, Oh YL. Thyroid pathology, a clue to PTEN hamartoma tumor syndrome. J. Pathol. Transl. Med. 2023; 57; 178–183.
Zambrano E, Holm I, Glickman J et al. Abnormal distribution and hyperplasia of thyroid C‐cells in PTEN‐associated tumor syndromes. Endocr. Pathol. 2004; 15; 55–64.
Cameselle‐Teijeiro J, Fachal C, Cabezas‐Agrícola JM et al. Thyroid pathology findings in Cowden syndrome: a clue for the diagnosis of the PTEN hamartoma tumor syndrome. Am. J. Clin. Pathol. 2015; 144; 322–328.
Bandargal S, Rajab M, Forest V‐I et al. Characteristics of PTEN mutation in thyroid tumours: a retrospective chart review. Cancer 2023; 15; 1575.
Barletta JA, Bellizzi AM, Hornick JL. Immunohistochemical staining of thyroidectomy specimens for PTEN can aid in the identification of patients with Cowden syndrome. Am. J. Surg. Pathol. 2011; 35; 1505–1511.
Huang SC, Lee JK, Smith EJ et al. Evidence for an hMSH3 defect in familial hamartomatous polyps. Cancer 2011; 117; 492–500.
Thompson LDR, Poller DN, Kakudo K, Burchette R, Nikiforov YE, Seethala RR. An international interobserver variability reporting of the nuclear scoring criteria to diagnose noninvasive follicular thyroid neoplasm with papillary‐like nuclear features: a validation study. Endocr. Pathol. 2018; 29; 242–249.
Gimm O, Perren A, Weng LP et al. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am. J. Pathol. 2000; 156; 1693–1700.
Acquaviva G, Visani M, Repaci A et al. Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance. Histopathology 2018; 72; 6–31.
Yehia L, Eng C. PTEN hamartoma tumour syndrome: what happens when there is no PTEN germline mutation? Hum. Mol. Genet. 2020; 29; R150–R157.